SCA Pharma CEO Milton Boyer and Vice President Matt White, PharmD, joined leading industry experts for the FDA’s inaugural Compounding Quality Center of Excellence Virtual Conference Sept. 21-22.
Milton and Matt participated in the panel discussion, “Incorporating automation and technology into compounding.”
“We appreciate the opportunity to participate in the dialogue between Industry and the FDA,” Milton said. “These events are important for SCA, the 503B industry as a whole and ultimately patient safety.”
“We were pleased to join members of the 503B industry and our regulatory partners and stakeholders in this important conference,” Milton said. “The outsourcing industry has been a vital supplier of critical medicines, especially during COVID-19”
The conference brought together current and future outsourcing facilities, regulators, compounding experts and stakeholders to discuss a range of diverse topics surrounding the industry. Key issues included policies and experiences during COVID-19, current good manufacturing practices (CGMP), automation technology and more.
FDA Commissioner Dr. Stephen H. Hahn provided opening remarks.
Date: September 21-22, 2020